chr10-99713461-A-G
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_004376.7(COX15):āc.1120T>Cā(p.Phe374Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.868 in 1,613,432 control chromosomes in the GnomAD database, including 609,113 homozygotes. In-silico tool predicts a benign outcome for this variant. 10/12 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_004376.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COX15 | NM_078470.6 | c.*1126T>C | 3_prime_UTR_variant | 9/9 | ENST00000016171.6 | NP_510870.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COX15 | ENST00000370483.9 | c.1120T>C | p.Phe374Leu | missense_variant | 9/9 | 1 | ENSP00000359514.5 | |||
COX15 | ENST00000016171 | c.*1126T>C | 3_prime_UTR_variant | 9/9 | 1 | NM_078470.6 | ENSP00000016171.6 | |||
ENSG00000285932 | ENST00000649102.1 | n.*460+2887T>C | intron_variant | ENSP00000497114.1 | ||||||
CUTC | ENST00000493385.5 | n.117-9457A>G | intron_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.841 AC: 127802AN: 151960Hom.: 53984 Cov.: 31
GnomAD3 exomes AF: 0.864 AC: 214132AN: 247958Hom.: 92694 AF XY: 0.867 AC XY: 116460AN XY: 134306
GnomAD4 exome AF: 0.871 AC: 1272771AN: 1461354Hom.: 555098 Cov.: 53 AF XY: 0.872 AC XY: 633758AN XY: 726996
GnomAD4 genome AF: 0.841 AC: 127891AN: 152078Hom.: 54015 Cov.: 31 AF XY: 0.842 AC XY: 62576AN XY: 74356
ClinVar
Submissions by phenotype
not specified Benign:5
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 01, 2011 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Likely benign, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | - | Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. - |
Benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 10, 2018 | Variant summary: COX15 c.1120T>C (p.Phe374Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.86 in 273702 control chromosomes (gnomAD), suggesting that it is the major allele and therefore benign. The observed variant frequency is approximately 690-fold higher than the estimated maximal expected allele frequency for a pathogenic variant in COX15 causing Leigh Syndrome phenotype (0.0013), strongly suggesting that the variant is benign. To our knowledge, no occurrence of c.1120T>C in individuals affected with Leigh Syndrome and no experimental evidence demonstrating its impact on protein function have been reported. Two ClinVar submission from other clinical diagnostic laboratories (evaluation after 2014) cite the variant as benign. Based on the evidence outlined above, the variant was classified as benign. - |
not provided Benign:3
Benign, no assertion criteria provided | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Feb 15, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Leigh syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at